Please assess the completion status of the following clinical trial:

Trial Title: UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed informed consent and willing to comply with protocol-specified procedures.~* Has any confirmed UCD other than N-acetyl glutamatesynthase (NAGS) deficiency.~* Is male or female, 12 to 70 years of age (inclusive)~* If ≥ 18 years old, has a BMI ≥20.0 and \< 40.0 kg/m2. If \< 18 years old, has a BMI between 5th percentile and 95th percentile and weight greater than 5th percentile according to age, sex and regionally appropriate growth chart~* Has evidence of poorly controlled disease on the current standard of care (SOC)~* If NBT is part of SOC, is on a stable dose and regimen for at least 4 weeks before Screening and the dose is expected to remain stable during the study~* Is willing to maintain a stable diet throughout the course of study and is willing to continue usual exercise routine.~* If taking probiotics or prebiotics, is on a stable dose regimen for at least 4 weeks before Screening and the dose and regimen are expected to remain stable during the study~* Has a negative urine screen for drugs of abuse at Screening~* If male or female of child bearing potential, agree with use effective method of contraception for the duration of the study and 90 days after last dose of study product~Key Exclusion Criteria:~* Is at a high risk for metabolic decomposition.~* Has had a substantive change in diet or any other aspect of UCD management within 4 weeks before the Screening Visit~* Has used a systemic anti-infective within 4 weeks before the Screening Visit, or use is anticipated during the study~* Has been diagnosed with Citrullinemia Type II~* Is receiving any systemically administered immunosuppressant medication on a chronic basis~* Has changed the use of or dose of any drug or other compound to modulate GI motility within 4 weeks before the Screening Visit, or the use or dose is expected change during the course of the study~* Has a history of or active GI or liver disease~* Has a prior solid organ transplantation including liver transplantation, or is anticipated to receive a liver transplant during study participation~* Has used an investigational drug, product, or device within 30 days before the Screening Visit~* Has a contraindication, sensitivity, or known allergy to the study drug~* Is considered, in the opinion of the PI, to likely be a poor attendee or unlikely for any reason to be able to comply with the study drug procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- KB195 (Type: EXPERIMENTAL): KB195 is a novel glycan

Based on this trial design, predict the completion outcome and termination type (if applicable).